Caplin Point Laboratories enterprise value

Share price at each year-end

Tap a line for its trend	Currentlast 12M	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus


18,058	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
480	480	511	377	337
44.4	44.4	35.9	31.1	26.8
0.6	0.6	0.6	1.2	3.4
17,623	—	—	—	—
−479	−479	−510	−375	−333
₹2,318.87	—	—	—	—

3,631	3,631	2,887	2,348	1,911
0.0%	0.0%	0.0%	0.1%	0.2%
0.00×	—	—	—	—

7.70×	—	—	—	—
22.12×	—	—	—	—
24.53×	—	—	—	—
64.06×	—	—	—	—
2,287	2,187	1,937	1,694	1,467
797	761	647	551	441
718	688	581	498	396
—	523	432	311	272
275	275	241	165	77.9
—	275	241	165	77.8
—	248	192	146	194

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

CAPLIPOINT₹2,376.10

Caplin Point Laboratories Ltd.

· Pharma & Health

₹ CrorePeersAJANTPHARM ERIS GLAND BLUEJET CONCORDBIO ACUTAAS EMCURE GRANULESMcap ₹18,058 Cr

HighlightsEnterprise Value Multiples Per ShareAnnuals · FY-end closes

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Current/LTM TTM · last close
Market Capitalization	—	—	—	—	18,058.4
- Cash, Equiv & ST Investments	336.7	376.7	510.8	479.9	479.9
+ Minority Interest	26.8	31.1	35.9	44.4	44.4
+ Total Debt	3.4	1.2	0.6	0.6	0.6
Enterprise Value	—	—	—	—	17,623.4
Net Debt (memo)	-333.3	-375.5	-510.2	-479.3	-479.3
EV per Share	—	—	—	—	2,318.87

Total Capital	1,910.7	2,348.0	2,886.9	3,631.4	3,631.4
Total Debt/Total Capital	0.18	0.05	0.02	0.02	0.02
Total Debt/EV	—	—	—	—	0.00

EV/Sales	—	—	—	—	7.70
EV/EBITDA	—	—	—	—	22.12
EV/EBIT	—	—	—	—	24.53
EV/Free Cash Flow	—	—	—	—	64.06
Reference Items — Trailing FY Values
Sales	1,466.7	1,694.1	1,937.5	2,187.2	2,287.3
EBITDA	441.1	551.4	646.9	760.9	796.6
EBIT	396.1	498.0	581.0	688.1	718.5
Operating Cash Flow	271.7	311.0	432.4	523.2	—
Free Cash Flow	77.9	165.2	240.9	275.1	275.1
FCFF (free cash flow to the firm)	77.8	165.0	240.7	274.9	—
Capital Expenditure	193.8	145.8	191.5	248.1	—

Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.